FindTrial
Sign In

F520

DRUG5 trials

Sponsors

Shandong New Time Pharmaceutical Co., LTD

Conditions

Locally Advanced or Metastatic Urothelial Cell CarcinomaNSCLCNon-small Cell Lung CancerPD-1Peripheral T Cell LymphomaPrimary Central Nervous System LymphomaSecondary Central Nervous System LymphomaSolid Tumors

Phase 1

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
NCT05740215
Shandong New Time Pharmaceutical Co., LTDSolid Tumors
Start: 2022-05-23End: 2024-05-22Target: 158Updated: 2023-02-22

Phase 2

A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
NCT04457869
Shandong New Time Pharmaceutical Co., LTDPrimary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Start: 2020-11-01End: 2023-01-01Target: 43Updated: 2020-10-22
The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
NCT04457830
Shandong New Time Pharmaceutical Co., LTDPeripheral T Cell Lymphoma
Start: 2020-11-01End: 2023-01-01Target: 105Updated: 2020-10-22
A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma
NCT04636515
Shandong New Time Pharmaceutical Co., LTDLocally Advanced or Metastatic Urothelial Cell Carcinoma
Start: 2021-01-31End: 2022-09-30Target: 80Updated: 2020-11-19
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05741021
Shandong New Time Pharmaceutical Co., LTDNon-small Cell Lung Cancer, NSCLC, PD-1
Start: 2023-03-01End: 2024-10-25Target: 84Updated: 2023-02-24